355
Views
49
CrossRef citations to date
0
Altmetric
Original Articles

Ginsenoside Rg1 inhibits β-secretase activity in vitro and protects against Aβ-induced cytotoxicity in PC12 cells

&
Pages 604-612 | Received 15 Nov 2008, Accepted 23 Feb 2009, Published online: 03 Jul 2009
 

Abstract

Ginsenoside Rg1 (1) is a major active component of Panax notoginseng, a Chinese herb widely used in traditional Chinese medicine to improve learning and memory function. Increasing evidence suggests that β-amyloid peptide (Aβ) plays a central role in the pathophysiology of Alzheimer's disease (AD). To elucidate the mechanism of 1 on improving the ability of learning and memory, we investigated whether 1 could affect Aβ generation or protect Aβ-induced neurotoxicity. The results showed that 1 could inhibit β-secretase activity in vitro and also protect the PC12 cells against injuries caused by exposure of PC12 cells to 50 μM Aβ25-35 for 48 h. The cell death, LDH release, NO release, ROS production, lipid peroxidation, intracellular calcium elevation, and apoptosis are associated events induced by Aβ that can be rescued by 1 in PC12 cells. In conclusion, 1 may be a promising agent for AD, and the mechanism is related to β-secretase inhibition and protection against Aβ-induced cytotoxicity.

Acknowledgements

The present study was supported by the project (No. 30630073) from the National Natural Science Foundation of China and the project (No. 2006QN40) from the Young Foundation of Institute of Materia Medica, Chinese Academy of Medical Sciences.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.